In bladder cancer, the MAPK pathway is highly associated with FGFR3 mutations (Table 1), commonly observed in low-grade bladder cancer but also present in some patients with high-grade invasive bladder cancer, thereby enhancing the tumor’s invasiveness and metastatic potential (15). This evidence concerns the gene FGFR3 and urinary bladder cancer.